MedTrace Logo

Sodium-Endothelial Function-CKD Study

NCT00141622 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2007-05-15

No results posted yet for this study

Summary

Heart disease and stroke, known as cardiovascular disease, are major causes of death in people with chronic kidney disease. Abnormalities of a metabolic pathway called the "L-arginine-nitric oxide" pathway are thought to be particularly important in these people, and previous research in animals has suggested that sodium (salt) affects part of this metabolic pathway. The purpose of our research is to study the effects of sodium intake on the "L-arginine-nitric oxide" pathway, and on blood vessel function, in patients with kidney disease.

Conditions

  • Kidney Failure, Chronic

Interventions

DRUG

Slow sodium

Sponsors & Collaborators

  • British Heart Foundation

    collaborator OTHER

  • St. George's Hospital Charitable Foundation

    collaborator UNKNOWN

  • St George's, University of London

    lead OTHER

Principal Investigators

  • Timothy WR Doulton, BSc MRCP · SGUL

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2006-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00141622 on ClinicalTrials.gov